Letrozole in Treating Breast Cancer in Postmenopausal Women With Stage I, II, or III Breast Cancer Previously Treated With Tamoxifen (GIM4)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Lucia Del Mastro,MD, National Institute for Cancer Research, Italy
ClinicalTrials.gov Identifier:
NCT01064635
First received: February 5, 2010
Last updated: May 22, 2015
Last verified: May 2015

February 5, 2010
May 22, 2015
August 2005
August 2015   (final data collection date for primary outcome measure)
Disease-free survival [ Time Frame: 6 years after the last patient enters the study ] [ Designated as safety issue: No ]
Disease-free survival [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01064635 on ClinicalTrials.gov Archive Site
  • Overall survival [ Time Frame: 6 years after the last patient enters the study ] [ Designated as safety issue: No ]
  • Safety [ Time Frame: 6 years after the last patient enters the study ] [ Designated as safety issue: Yes ]
  • Overall survival [ Designated as safety issue: No ]
  • Safety [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Letrozole in Treating Breast Cancer in Postmenopausal Women With Stage I, II, or III Breast Cancer Previously Treated With Tamoxifen (GIM4)
Letrozole Adjuvant Therapy Duration (LEAD) Study: Standard Versus Long Treatment. A Phase III Trial in Post-Menopausal Women With Early Breast Cancer.

RATIONALE: Estrogen can cause the growth of breast cancer cells. Letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known which regimen of letrozole is most effective in treating breast cancer in postmenopausal women who have received tamoxifen.

PURPOSE: This randomized phase III trial is comparing different regimens of letrozole to see how well they work in treating postmenopausal women with stage I, stage II, or stage III breast cancer previously treated with tamoxifen.

OBJECTIVES:

Primary

  • To compare the disease-free survival of previously treated, post-menopausal women with early-stage breast cancer treated with standard- (2-3 years of tamoxifen followed by 2-3 years of letrozole) versus long-treatment (2-3 years of tamoxifen followed by 5 years of letrozole) adjuvant letrozole.

Secondary

  • To compare the overall survival of these patients.
  • To compare the safety of these patients.

OUTLINE: Patients are randomized to 1 or 2 treatment arms.

  • Arm I (standard treatment): Patients previously treated with tamoxifen for 2 years receive letrozole for an additional 3 years; patients previously treated with tamoxifen for 3 years receive letrozole for an additional 2 years; and patients previously treated with tamoxifen for 2-3 years receive letrozole , so the total duration of the endocrine treatment (i.e., tamoxifen followed by letrozole) is 5 years.
  • Arm II (long treatment): Patients receive letrozole for an additional 5 years regardless of the duration of the previous tamoxifen treatment.
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Breast Cancer
  • Drug: Letrozole
    letrozole for 2-3 years after Tam
  • Drug: Letrozole
    Letrozole for 5 years after Tam
  • Active Comparator: Letrozole for 3-2 years
    Patients pre-treated with TAM for 2-3 years will receive letrozole 2,5 mg/die for 3-2 years. Total duration of early adjuvant endocrine therapy: 5 years
    Intervention: Drug: Letrozole
  • Experimental: Letrozole for 5 year
    Patients pre-treated with TAM for 2-3 years will receive letrozole 2,5 mg/die for additional 5 years. Total duration of early adjuvant endocrine therapy: 7 years for patients pretreated with 2 years of TAM and 8 years for patients pre-treated with 3 years of TAM
    Intervention: Drug: Letrozole
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
2056
Not Provided
August 2015   (final data collection date for primary outcome measure)

INCLUSION CRITERIA

  • Signed informed consent prior to beginning protocol specific procedures.
  • Histologically proven breast cancer at the first diagnosis with tumor stage I-II-III. Patients with histologically documented (microscopic) infiltration of the skin (pT4) will also be eligible.
  • Axillary Nodal status allowed: Nx, pNo, pN1, pN2, PN3.
  • Postmenopausal status defined by one of the following:

    • Age > 55 years with cessation of menses
    • Age < 55 years but not spontaneous menses for at least 1 year
    • Age < 55 years and spontaneous menses within the past 1 year, but currently amenorrheic (e.g. spontaneous, or secondary to hysterectomy), AND with postmenopausal gonatrophin levels (luteinizing hormone and follicle stimulating hormone levels >40 IU/L) or postmenopausal estradiol levels (<5 ng/dL) or according to the definition of "postmenopausal range" for the laboratory involved.
    • Bilateral oophorectomy
  • Adjuvant TAM received for at least 2 years and not more than 3 years and 3 months. Patients treated with adjuvant chemotherapy, are required to have begun receiving TAM within 3 months after the completion of chemotherapy.
  • Definitive surgical treatment must be either mastectomy or breast conserving surgery, with axillary lymph node dissection or sentinel node biopsy for operable breast cancer.
  • ECOG/WHO performance Status 0-1. Patients must be accessible for treatment and follow-up.
  • Concomitant treatment with biphosphonates are allowed and should be recorded during the trial.

EXCLUSION CRITERIA

  • Male patients.
  • Any locally advanced (T4) or inflammatory breast cancer. However, patients with microscopic infiltration of the skin (pT4) will be eligible.
  • Patients with distant metastases. Any suspicious manifestation requires appropriate investigation to exclude metastases.
  • Histology other than adenocarcinoma.
  • Patients with previous or concomitant (not breast cancer) malignancy within the past 5 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix. Patients who have had a previous other malignancy must have been disease free for 5 years.
  • Patients with other non-malignant systemic diseases (cardiovascular, renal, hepatic, lung embolism, etc.) which would prevent prolonged follow-up.
  • Use of hormone Replacement Therapy within four weeks before randomization.
  • Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational regimen within 30 days prior to study entry.
  • Concurrent treatment with any other anti-cancer therapy.
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Italy
 
NCT01064635
CDR0000665188, GIM-4-LEAD, 2005-001212-44, EU-21003
Not Provided
Lucia Del Mastro,MD, National Institute for Cancer Research, Italy
National Institute for Cancer Research, Italy
Not Provided
Principal Investigator: Lucia Del Mastro, MD National Institute for Cancer Research, Italy
National Institute for Cancer Research, Italy
May 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP